HERPESVIRUS COMPOSITIONS AND RELATED METHODS
The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable exetpients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compostions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.
1 . A composition comprising a live, attenuated or genetically modified herpesvirus, and at least two or more pharmaceutically acceptable excipients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol.
2 . The composition of claim 1 , wherein the composition further comprises at least one or more additional pharmaceutically acceptable excipients selected from buffers, salts, surfactants, bulking agents, chelating agents, gelling agents, urea, albumin or combinations thereof.
3 . The composition of claim 1 , further comprising one or more buffers selected from the group consisting of TRIS (tris(hydroxymethyl)-aminomethane) and TRIS-acetate, and wherein the composition has a pH of about 6.5 to 7.5.
4 . The composition of claim 2 , further comprising one or more salts selected from the group consisting of sodium glutamate, potassium glutamate, sodium chloride, potassium chloride, and calcium chloride.
5 . The composition of claim 2 , further comprising urea and/or albumin.
6 . The composition of claim 1 , wherein the sugar or sugar alcohol is selected from the group consisting of sucrose, trehalose and sorbitol.
7 . The composition of claim 6 , comprising one or more sugar or sugar alcohols.
8 . The composition of claim 6 , wherein the sugar comprises sucrose.
9 . The composition of claim 8 , comprising 1 mM to 50 mM histidine and 5% to 10% w/v sucrose and having a pH of about 6.5 to 7.5.
10 . The composition of claim 9 , further comprising 1 mM to 100 mM potassium glutamate or sodium glutamate.
11 . The composition of claim 9 , further comprising 80 mM to 160 mM sodium chloride and has a pH of about 6.5 to 7.5.
12 . The composition of claim 1 , wherein the composition comprises 10 mM histidine, 10% w/v sucrose, 160 mM NaCl, 50 mM potassium glutamate and a pH of about 6.5 to 7.5.
13 . The composition of any one of claims 1 to 12 , wherein the composition is a liquid.
14 . The composition of claim 13 , wherein the liquid composition has a titre loss of less than 0.3 Logic pfu/mL following storage at 2-8° C. for 1-2 weeks.
15 . The composition of claim 13 , wherein the liquid composition has a titre loss of less than 0.5 Log 10 pfu/mL following storage at 25° C.±2° C. for 1 week.
16 . The composition of any one of claims 1 to 12 , wherein the composition is in a dried form.
17 . The composition of any one of claims 1 to 16 , wherein the live, attenuated or genetically modified herpesvirus is a herpes simplex virus 2 (HSV-2).
18 . The composition of claim 17 , wherein the HSV-2 is a replication defective HSV-529 strain.
19 . The composition of claim 17 or 18 , wherein the HSV-2 contains less than 10 ng of host cell DNA per 1×10 7 pfu/mL.
20 . The dried composition of claim 16 , wherein following storage for 6 months at 5° C.±2° C., the composition retains an infectious titre within 0.25 Log 10 pfu/ml of the titre measured after the composition is dried, when the viral titres in the composition are between 10 7 to 10 5 pfu/mL before drying.
21 . The dried composition of claim 16 , wherein following storage for 6 months at 5° C.±2° C., the composition retains an infectious titre within 0.2 Logo pfu/ml of the titre measured after the composition is dried, when the viral titres in the composition are between 10 7 to 10 5 pfu/mL before drying.
22 . The dried composition of claim 16 , wherein following storage for 6 months at 5° C.±2° C., the dried composition retains an infectious titre within 0.1 Log 10 pfu/ml of the titre measured after the composition is dried, when the viral titres in the composition are between 10 7 to 10 5 pfu/mL before drying.
23 . The dried composition of claim 16 , wherein following storage for 6 months at 25° C.±2° C., the dried composition retains an infectious titre within 0.5 Log 10 pfu/mL of the titre measured after the composition is dried, when the viral titres in the composition range from 10 7 to 10 5 pfu/mL before drying.
24 . The composition of any one of claims 16 to 23 , wherein the composition is freeze-dried, foam-dried or spray-dried.
25 . The composition of claim 24 , wherein the residual moisture content of the composition is 6% or less.
26 . The composition of any one of claims 1 to 25 , wherein the herpesvirus is grown using serum-free media.
27 . The composition of any one of claims 1 to 26 , wherein the composition is a pharmaceutical composition.
28 . The composition of claim 27 , wherein the composition is a vaccine.
29 . A method of manufacturing a dried composition comprising a live, attenuated or genetically modified herpesvirus and stabilizer that comprises at least two or more pharmaceutically acceptable excipients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol, the method comprising:
(i) admixing the live, attenuated or genetically modified herpesvirus with the stabilizer; and
(ii) drying the admixture.
30 . The method of claim 29 , wherein the admixture is dried by means of a method selected from the group of consisting of freeze-drying, foam-drying, and spray-drying.
31 . The method of claim 30 comprising a replication-defective herpes simplex virus.
32 . A method of preparing a vaccine, comprising reconstituting the dried composition of any one of claims 16 or 20 to 25 with an aqueous solution.
33 . A kit comprising a first container containing the dried composition as claimed in any one of claims 16 or 20 to 25 and a second container containing an aqueous solution for reconstituting the dried composition.